When the Science Isn't There: How Peptide Marketing Claims Are Becoming the DOJ's Easiest Wire Fraud Cases

If you sell, prescribe, or promote peptides, the most dangerous evidence the government will collect is not the product. It is the marketing copy.

Every Instagram post, clinic webpage, and promotional text is now a building block in a federal case the DOJ is increasingly comfortable bringing.

Every Instagram post, every clinic webpage, every text message promising "anti-aging," "fat loss," or "accelerated healing" is a building block in a federal case the DOJ is increasingly comfortable bringing.

A McMaster University professor published a piece this week summarizing what FDA enforcement attorneys have been saying privately for two years. The science behind the most popular peptides is thin. Most of what is sold to the public has never been tested in humans in any meaningful way. That gap between marketing claims and clinical evidence is where federal exposure is concentrated.

For physicians, clinic owners, compounding pharmacies, telehealth platforms, and marketing affiliates, the legal calculus has shifted. The question is no longer whether peptides are regulated. They are. The question is whether the way you describe your products gives a federal prosecutor everything needed to charge wire fraud, misbranding, and distribution of unapproved drugs at the same time.

What the New Reporting Actually Says

A peer-credentialed researcher at McMaster University published an analysis this week titled "The peptide problem: Hype is outrunning the evidence." The piece is a precise, sourced takedown of the marketing claims driving the grey-market peptide industry. Three points matter for legal exposure.

First, Health Canada issued a public advisory warning Canadians not to buy or inject unauthorized peptide drugs sold online, naming BPC-157, CJC-1295, ipamorelin, TB-500, and retatrutide by name. The advisory cites marketing for anti-aging, weight loss, recovery, sleep, mental focus, and "wellness." Several products have already been seized.

Second, the published human evidence for BPC-157, the most heavily marketed peptide in the wellness space, is essentially nonexistent. A retrospective knee-pain report covered 16 patients. An interstitial cystitis pilot covered 12 women. One systematic review of 544 papers found 35 of the 36 included studies were rodent or cell studies. There is no body of human clinical evidence supporting the recovery, anti-aging, or fat-loss claims being made online by clinics and influencers.

Third, the "third-party certificate of analysis" defense that vendors and clinics rely on does not hold up. The labs producing those certificates are often the vendors themselves, and a certificate showing 98 percent purity does not meet pharmaceutical standards. The reliance on outside purity tests is itself an admission that normal pharmaceutical guardrails are absent. Federal prosecutors will read that line the same way.

This is published, sourced, professional commentary that a federal prosecutor can hand to a grand jury. It is already appearing in indictments.

The misrepresentation element of wire fraud gets easier to prove, not harder, when efficacy claims are unsupported by human clinical evidence.

The July 2026 FDA Meeting Does Not Help You Right Now

The Pharmacy Compounding Advisory Committee is scheduled to meet July 23 and 24, 2026, on whether BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon should be added to the 503A Bulks List. Twelve peptides were removed from Category 2 in April 2026 after nominations were withdrawn.

None of that changes current legal status. Removal from Category 2 does not confer Category 1 status. The PCAC has not voted. The FDA has not added a single peptide to the 503A Bulks List. Until a peptide is on that list, compounding pharmacies cannot legally compound it for human use, clinics cannot administer it, and online vendors cannot sell it for human consumption.

Operating in anticipation of a regulatory change that has not happened is one of the patterns federal prosecutors point to when arguing willfulness. "I thought it was about to be legal" is not a defense. It is closer to evidence of intent.

Why the DOJ Treats Marketing Claims as Wire Fraud

Federal investigators in the peptide space are running parallel theories. The drug-side charges — distribution of unapproved drugs under the FDCA and misbranding under 21 U.S.C. §§ 331 and 333 — are the foundation. The fraud-side charges are what add years of prison exposure.

When efficacy claims are unsupported by human clinical evidence, the misrepresentation element gets easier to prove, not harder. The Stuart Phillips analysis, the Health Canada advisory, and the FDA's own briefing materials at past PCAC meetings establish the same record. The science is not there. Anyone selling these products knows or should know the marketing claims outrun the evidence. That knowledge converts a regulatory violation into a federal felony.

Healthcare fraud under 18 U.S.C. § 1347 layers on top when peptide services are billed to Medicare, Medicaid, or commercial insurers. Telehealth platforms billing wellness visits that result in peptide prescriptions are a current enforcement priority. Anti-Kickback Statute violations under 42 U.S.C. § 1320a-7b come into play when influencers, clinics, or telehealth platforms exchange anything of value for patient referrals. Drug importation charges under 21 U.S.C. § 331(d) and 18 U.S.C. § 545 follow when the source is overseas. Money laundering under 18 U.S.C. § 1956 follows when the proceeds move through business accounts.

The Tailor Made Compounding case in Kentucky resulted in a felony plea, $1.79 million in forfeiture, and a federal sentence for the principal. The All American Peptide case produced over $3 million in forfeitures and personal guilty pleas. The Paradigm Peptides case in the Northern District of Indiana produced two guilty pleas in December 2025, with sentencing in July 2026. These are the template prosecutors are using.

The Mistakes Operators Are Making Right Now

Most people in this space are not bad actors. They are physicians, clinic owners, telehealth founders, and entrepreneurs who built businesses inside what looked like a regulatory grey zone and are now watching the zone disappear. The mistakes they make in the early stages of an investigation are consistent.

Talking to FDA inspectors or DOJ agents without counsel is the most common. By the time an agent shows up at a clinic or warehouse, there is already a file. The visit is not fact-finding. It is an opportunity to lock in admissions. Statements about your knowledge of a peptide's regulatory status, your supplier, or the basis for your marketing claims appear verbatim in indictments.

Sanitizing websites or email archives after receiving a warning letter or subpoena is the second. Federal obstruction charges under 18 U.S.C. § 1519 are easier to prove than the underlying FDCA violation. Multiple peptide cases have been driven by deletion of records after the operator knew an investigation was underway. The Tailor Made Compounding principal made that mistake in 2018, and it escalated his sentence.

Continuing to operate after receiving a warning letter is the third. A warning letter is the document the government uses to establish that you knew the conduct was illegal. Continuing to ship product, prescribe, or market after a warning letter converts what might have been a civil matter into willful conduct supporting felony charges.

Trusting that "research use only" or "not for human consumption" disclaimers will provide cover is the fourth. The intended use doctrine looks at how the product is actually marketed and sold. A "not for human consumption" label on a vendor site that also publishes dosing protocols, mixing instructions, and patient testimonials is not a shield. It is evidence of intent to deceive.

By the time agents arrive, there is already a file. The visit is not fact-finding.

What an Effective Defense Looks Like Before Indictment

The window to influence a peptide investigation closes the moment an indictment is filed. Before that, there is real leverage. Federal prosecutors in this space are still developing their charging templates, and the cases they bring are negotiated. The decisions made in the first 30 days after a warning letter, subpoena, or agent contact often determine whether a matter resolves with a corporate civil settlement, a deferred prosecution agreement, an individual misdemeanor plea, or a multi-count felony indictment.

The goal at this stage is not to win at trial. It is to influence whether there is a trial at all. Pre-indictment intervention has resolved peptide cases as no-action declinations, civil-only enforcement, deferred prosecution agreements, and sentence reductions of years. Post-indictment, those options narrow and the leverage shifts.

Why Timing Matters

The peptide industry is in a six-to-eighteen-month window where the regulatory framework will harden in one direction or another. The PCAC meets in July. Rulemaking will follow. Enforcement priorities will be set or reset. None of that helps anyone currently under investigation, because the conduct prosecutors are looking at happened before any new rule takes effect. Federal cases are built on what the law was at the time of the conduct, not what it might become.

For operators with current exposure, the question is whether to position now, while the government is still building its case and prioritizing targets, or to wait and respond after charges are filed. That is the wrong choice to leave to chance.

The cases prosecutors bring in this space are negotiated. Pre-indictment intervention is where they are won.

Facing a Federal Investigation in the Peptide Industry?

AMC Defense Law represents physicians, clinic operators, compounding pharmacies, telehealth platforms, marketing affiliates, and wellness entrepreneurs in FDA, DOJ, and state-level investigations nationwide. Pre-indictment intervention is where these cases are won.

Aaron M. Cohen handles peptide-industry investigations with disciplined evidence analysis, marketing-copy review, and direct engagement with federal counsel.

If you have received an FDA warning letter, a grand jury subpoena, a target letter, or an OCI agent contact, contact AMC Defense Law for a confidential consultation. We handle cases throughout Florida and represent clients in federal courts nationwide.

The information in this article is for general informational purposes only and does not constitute legal advice. Reading this article does not create an attorney-client relationship. Legal outcomes depend on the specific facts of each matter.